AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02248415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection: the first postoperative day (T3)
Description: The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
Study NCT02703220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia/oxygen
Description: The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
Study NCT02703220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
Study NCT02703220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
Study NCT00721123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab (myeloma receptor antibody \[MRA\]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
Study NCT03054753 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Abduction brace wearing time analysis
Description: To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
Study NCT02128906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 weekly x 7
Study NCT02128906 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT: once daily, M-F, 7 weeks (70 Gy)
Study NCT02128906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 15 mg/m2 weekly x 7
Study NCT02128906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
Study NCT03473951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperuricemia
Description: Hyperuricemia vs. normouricemia
Study NCT00814866 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adalimumab
Description: Adalimumab 40 mg sub-cutaneously every two weeks
Study NCT03388385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: Physiologic saline infusion will be infused in day 1.
Study NCT03388385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Intravenous Solution
Description: Physiologic saline infusion will be infused in day 1.
Study NCT03388385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: Ferric carboxymaltose will be infused in day 2.
Study NCT03388385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject
Description: Ferric carboxymaltose will be infused in day 2.
Study NCT02420158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-cutaneous vagal nerve electrical stimulation
Study NCT03894046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulbactam
Description: 1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h).
Study NCT03894046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlobactam
Description: 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h).~Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated.
Study NCT03894046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Treatment for 7 days up to 14 days if clinically indicated.
Study NCT03894046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Cilastatin 500 mg/500 mg
Description: 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
Study NCT03894046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/Cilastatin 500 mg/500 mg
Description: 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated.
Study NCT01526772 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Transoral endoscopy versus transoral endoscopy
Study NCT03364569 — intervention group
Intervention type: PROCEDURE
Intervention: Tranexamic acid
Description: Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
Study NCT03606044 — intervention group
Intervention type: DEVICE
Intervention: 3D-models
Description: The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly
Study NCT00611533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Study NCT00611533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Study NCT05922956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Facial emotion recognition test
Description: Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Study NCT05922956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition test
Description: Facial emotion recognition test (TREF), questionnaires including self-administered questionnaires
Study NCT01006460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea, L
Description: 3 Capsules twice a day
Study NCT01006460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis
Description: 3 capsules twice a day
Study NCT02292199 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS Placebo
Description: TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
Study NCT01006460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panax ginseng
Description: 3 capsules twice a day
Study NCT01006460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - dark brown sugar
Description: 3 capsules twice a day
Study NCT01781533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: algorithm
Study NCT02262741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 will be administered by IV infusion in combination with tremelimumab.
Study NCT02262741 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tremelimumab
Description: Tremelimumab will be administered by IV infusion in combination with MEDI4736.
Study NCT02860325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV-NAVA
Description: Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
Study NCT02860325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
Study NCT02126657 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 70% glycolic acid
Study NCT01345734 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
Study NCT00006467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Study NCT04676412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT01460277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy Intervention
Description: The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
Study NCT01460277 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Land-based exercise intervention
Description: The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
Study NCT04676412 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04676412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: oral capsule
Study NCT01629563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 5 mg
Description: PGL4001 5 mg daily administration
Study NCT01629563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001 10 mg
Description: PGL4001 10mg daily administration
Study NCT03578172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human menopausal gonadotrophin
Description: experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)\<100pg/ml，progesterone (P)\<1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
Study NCT03578172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hormone replacement therapy
Description: Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration >60 days.
Study NCT00530257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sugar pill)
Study NCT00530257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OROS-methylphenidate
Description: 18 mg to 54 mg once a day for 1 week
Study NCT00385515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-1012 (meclocycline sulfosalicylate)
Description: tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
Study NCT04676412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: oral capsule
Study NCT04034082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia therapy
Description: Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
Study NCT05379361 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Intelligence Development Program
Description: It is a training program that was developed in line with the literature and preliminary research results and includes the bar-on emotional intelligence sub-dimensions.
Study NCT05379361 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasebo Training Group
Description: It is a training program that was developed in line with the literature and includes the environmental awareness skills education.
Study NCT03066817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]
Description: 50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
Study NCT03066817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propylene Glycol
Description: 50cc of propylene glycole will be given to participants as one-time dose, used as placebo
Study NCT03517046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CartiLife
Description: Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
Study NCT04034082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phase 2 cardiac rehabilitation programme
Description: The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
Study NCT04034082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional phase 2 cardiac rehabilitation programme
Description: The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ecological evaluation
Description: Virtual reality task and Actual reality
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological evaluation
Description: Virtual reality task and Actual reality
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation
Description: cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue
Study NCT03455582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological evaluation
Description: questionnaires for depression, anxiety and fatigue
Study NCT03455582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study NCT03455582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Evaluation
Description: morphological MRI and resting state functional MRI (fMRI)
Study NCT03416907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original consent form
Description: Participants will review the full-length, original consent form for the clinical trial.
Study NCT03416907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortened consent form
Description: Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
Study NCT03416907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reordered, shortened consent form
Description: Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
Study NCT03416907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortened consent form with a highlights box
Description: Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
Study NCT03416907 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive, shortened consent form
Description: Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
Study NCT03343067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: Tablets
Study NCT03343067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol/norethindrone acetate (E2/NETA)
Description: Capsules
Study NCT01031602 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
Study NCT04373174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regional oximetry probe
Description: Regional oximetry probe will be placed in the frontal area of the head
Study NCT04373174 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Regional oximetry probe
Description: Regional oximetry probe will be placed in the frontal area of the head
Study NCT04373174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural block
Description: Thoracic epidural block will be applied to the patients before the operation begins
Study NCT01050543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
Study NCT01050543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
Study NCT03105804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21039
Description: An electronic cigarette
Study NCT03105804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21041
Description: An electronic cigarette
Study NCT03105804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21044
Description: An electronic cigarette
Study NCT03105804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FT21042
Description: An electronic cigarette
Study NCT03704987 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual-energy X-ray absorptiometry
Description: dual-energy X-ray absorptiometry